IntraBio
This page is dedicated to news and information about IntraBio’s therapies for use in Niemann-Pick Disease Type C (NPC). Information is released as it becomes available.
ABOUT INTRABIO GLOSSARY OF TERMS
IntraBio IB1001-201 Clinical Trial for NPC Reaches 2/3 of their Recruitment Goal
.
CLICK HERE FOR COMPLETE ANNOUNCEMENT
11/13//2019 jjb
IntraBio Clinical Trial IB1001-201 Open for US Recruitment at Mayo Clinic
.
CLICK HERE FOR COMPLETE ANNOUNCEMENT
09/04/2019 jjb
IntraBio IB1001 Series Update
.
IntraBio is developing a number of small-molecule drug candidates that have broad applicability to rare and common neurological disorders, genetic, and inflammatory diseases. Their current lead drug candidate, IB1001, is initially being developed to treat three rare, genetic diseases where there are extremely high unmet medical needs: Niemann-Pick disease type C, GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and Ataxia-Telangiectasia (A-T; an inherited Cerebellar Ataxia). Click the link below for additional information.
.
CLICK HERE FOR IB1000 SERIES DEVELOPMENT HISTORY
05/31/2019 jjb
NNPDF Industry Update Webinar Series featuring IntraBio, Inc.
04/25/2019 jjb
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of NPC
.
CLICK HERE FOR COMPLETE ANNOUNCEMENT
03/11/2019 jjb
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of NPC
.
CLICK HERE FOR COMPLETE ANNOUNCEMENT
02/13/2019 jjb
IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB1000 Series
.
CLICK HERE FOR COMPLETE ANNOUNCEMENT
11/26/2018 jjb
